Home > Name List By other > (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino] thiophene-2-carbonyl]amino]pentanedioic acid

CAS No 112887-68-0 , (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]
thiophene-2-carbonyl]amino]pentanedioic acid

  • Name: (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]
    thiophene-2-carbonyl]amino]pentanedioic acid
  • Synonyms: D1694; ICI-D1694; ZD1694; 112887-68-0; ZD-1694; 2kce; 2tsr;(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]
    thiophene-2-carbonyl]amino]pentanedioic acid;Tomudex; ICI D1694;
  • CAS Registry Number:
  • Melting Point: 176-1800C
  • Flash Point: °C
  • Boiling Point: °Cat760mmHg
  • Density: 1.49 g/cm3
  • Refractive index: 1.638
  • Safety Statements: S26; S37/39
  • Hazard Symbols: Xi: Irritant;
  • Flash Point: °C
  • Molecular Weight: 458.48758
  • InchiKey: IVTVGDXNLFLDRM-HNNXBMFYSA-N
  • InChI: InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-
    7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,
    1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
  • Risk Statements: R36/38
  • Molecular Formula: C21H22N4O6S
  • Molecular Structure:CAS No:112887-68-0 (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]<br />thiophene-2-carbonyl]amino]pentanedioic acid
Search by region :

Select to

112887-68-0 Raltitrexed

  • China Xianju Belter Co., Ltd [Manufacturers]
  • Tel: +86-576-87785883
  • Fax: 0086-576-8779852
  • Address: Add.: Unit 2, No 4, Siyuanhong Alley, Chengguan Town, Xianju City, 317300, Zhejiang Province, China Taizhou,ZhejiangChina
Contact Supplier

112887-68-0 Raltitrexed

Contact Supplier

112887-68-0 Raltitrexed

  • China Hunan Steroid Chemicals Co., Ltd. [Manufacturers]
  • Tel: 0086 731 2762868
  • Fax: 0086 731 5551702
  • Address: Xin Wei Ming Zuo Bldg., No. 460, Shaoshan Rd, Changsha, Hunan 410007, Changsha,HunanChina
Contact Supplier

112887-68-0 Raltitrexed

Contact Supplier

112887-68-0 Raltitrexed

  • United States BRIDGEBIO null
  • Tel: 415 307 7617
  • Address: United States null,nullUnited States
Contact Supplier

112887-68-0 Raltitrexed

Contact Supplier

112887-68-0 Raltitrexed

Contact Supplier

112887-68-0 Raltitrexed

Contact Supplier

112887-68-0 Raltitrexed

  • China Hubei Gedian Humanwell Pharmaceutical Co., Ltd. [Manufacturers]
  • Tel: +86-27-87596825, +86-27-87597155
  • Fax: 86-27-87597383
  • Address: Room 303, Dangdai Bldg, NO.369 Lumo Road, Hongshan District, Wuhan 430074, Hubei, China Wuhan,hubeiChina
Contact Supplier

112887-68-0 Raltitrexed

  • China Jinan Lekangxin Pharmaceutical Co.,Ltd. null
  • Fax: +86-531-82373277, +86-531-82373278
  • Address: Rm.242,Building2,Returned Scholars Pioneer Park, 19 Huaneng Rd., Jinan,Shandong, China null,nullChina
Contact Supplier

Select to

References of (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]
thiophene-2-carbonyl]amino]pentanedioic acid
Title: Raltitrexed
CAS Registry Number: 112887-68-0
CAS Name: N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid
Synonyms: N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid
Manufacturers' Codes: ICI-D-1694; ZD-1694
Trademarks: Tomudex (AstraZeneca)
Molecular Formula: C21H22N4O6S
Molecular Weight: 458.49
Percent Composition: C 55.01%, H 4.84%, N 12.22%, O 20.94%, S 6.99%
Literature References: Folate-based inhibitor of thymidylate synthase; rapidly and extensively metabolized to its more potent polyglutamate derivatives. Prepn: L. R. Hughes, EP 239362 (1987 to ICI; Natl. Res. Dev.); idem, US 4992550 (1991 to ICI); P. R. Marsham et al., J. Med. Chem. 34, 1594 (1991). Pharmacokinetics: D. I. Jodrell et al., Cancer Chemother. Pharmacol. 28, 331 (1991). HPLC determn of metabolites in cultured cells: W. Gibson et al., Biochem. Pharmacol. 45, 863 (1993). Review of clinical toxicology: S. J. Clarke et al., Adv. Exp. Med. Biol. 338, 601-604 (1993); of mechanism of action: A. L. Jackman et al., ibid. 339, 265-276. Historical development, pharmacology, and clinical evaluation: S. J. Clarke et al., ibid. 277-287; A. L. Jackman et al., Eur. J. Cancer 31A, 1277-1282 (1995).
Properties: Pale yellow powder. Sol in water.
 
Derivative Type: Monohydrate
Molecular Formula: C21H22N4O6S.H2O
Molecular Weight: 476.50
Percent Composition: C 52.93%, H 5.08%, N 11.76%, O 23.50%, S 6.73%
Properties: mp 180-184°.
Melting point: mp 180-184°
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Antimetabolites; Folic Acid Analogs/Antagonists.